235 related articles for article (PubMed ID: 34960770)
1. INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.
Smith SJ; Ferris A; Zhao X; Pauly G; Schneider JP; Burke TR; Hughes SH
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960770
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
Mbhele N; Chimukangara B; Gordon M
Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
[TBL] [Abstract][Full Text] [Related]
4. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
Smith SJ; Zhao XZ; Burke TR; Hughes SH
Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.
Smith SJ; Zhao XZ; Burke TR; Hughes SH
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987149
[TBL] [Abstract][Full Text] [Related]
7. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
9. Comparable
Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
[TBL] [Abstract][Full Text] [Related]
11. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
Weber J; Rose JD; Vazquez AC; Winner D; Margot N; McColl DJ; Miller MD; Quiñones-Mateu ME
PLoS One; 2013; 8(6):e65631. PubMed ID: 23776513
[TBL] [Abstract][Full Text] [Related]
12. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
Yang LL; Li Q; Zhou LB; Chen SQ
Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
[TBL] [Abstract][Full Text] [Related]
14. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
16. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
Han YS; Mesplède T; Wainberg MA
Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
[TBL] [Abstract][Full Text] [Related]
17. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.
Hikichi Y; Van Duyne R; Pham P; Groebner JL; Wiegand A; Mellors JW; Kearney MF; Freed EO
mBio; 2021 Jan; 12(1):. PubMed ID: 33436439
[TBL] [Abstract][Full Text] [Related]
19. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
[TBL] [Abstract][Full Text] [Related]
20. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
